Replimune Group (NASDAQ:REPL) Hits New 12-Month High - What's Next?

Key Points

• Replimune shares hit a new 52-week high, reaching $13.90 before closing at $12.86, up 8.7% from the prior close. The stock’s 50-day and 200-day moving averages were $9.92 and $7.47, respectively.
• Analyst sentiment is mixed but leans positive, with a consensus rating of “Moderate Buy” and an average price target of $11.43. Recent actions included upgrades from Piper Sandler and BMO Capital Markets, alongside continued “sell” and “hold” ratings from other firms.
• The company reported a quarterly loss of $0.76 per share, missing the $0.66 consensus estimate, while analysts expect a full-year loss of $2.54 per share. Institutional investors own a substantial 92.53% of outstanding shares, and an insider recently sold 12,000 shares under a pre-arranged trading plan.

Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) shares reached a new 52-week high on Thursday . The company traded as high as $13.90 and last traded at $12.86, with a volume of 6196951 shares trading hands. The stock had previously closed at $11.83.

Analysts Set New Price Targets

A number of brokerages recently issued reports on REPL. Weiss Ratings raised Replimune Group from a "sell (e+)" rating to a "sell (d-)" rating in a report on Monday, July 20th. Piper Sandler raised Replimune Group from a "hold" rating to a "strong-buy" rating in a research note on Friday, July 31st. BMO Capital Markets upgraded Replimune Group from an "underperform" rating to an "outperform" rating and set a $16.00 price target for the company in a research report on Tuesday, June 30th. HC Wainwright reissued a "sell" rating on shares of Replimune Group in a research note on Monday, April 13th. Finally, Jefferies Financial Group reissued a "hold" rating and set a $2.00 price target (down from $13.00) on shares of Replimune Group in a report on Monday, April 13th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $11.43.

Replimune Group Stock Up 8.7%

The company has a debt-to-equity ratio of 0.63, a current ratio of 4.79 and a quick ratio of 4.79. The firm has a market capitalization of $1.08 billion, a P/E ratio of -3.80 and a beta of 0.88. The firm's fifty day moving average price is $9.92 and its 200-day moving average price is $7.47.

Replimune Group (NASDAQ:REPL - Get Free Report) last announced its earnings results on Monday, June 29th. The company reported ($0.76) EPS for the quarter, missing the consensus estimate of ($0.66) by ($0.10). As a group, equities research analysts forecast that Replimune Group, Inc. will post -2.54 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Christopher Sarchi sold 12,000 shares of Replimune Group stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $9.24, for a total transaction of $110,880.00. Following the transaction, the insider directly owned 180,962 shares of the company's stock, valued at $1,672,088.88. The trade was a 6.22% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.40% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Replimune Group

Several hedge funds have recently made changes to their positions in REPL. International Assets Investment Management LLC bought a new stake in Replimune Group during the fourth quarter worth approximately $29,000. Russell Investments Group Ltd. lifted its position in shares of Replimune Group by 3,638.9% during the 3rd quarter. Russell Investments Group Ltd. now owns 7,777 shares of the company's stock valued at $33,000 after acquiring an additional 7,569 shares during the last quarter. CWM LLC boosted its stake in shares of Replimune Group by 248.6% during the 4th quarter. CWM LLC now owns 4,047 shares of the company's stock worth $39,000 after acquiring an additional 2,886 shares in the last quarter. Essential Partners LLC grew its holdings in shares of Replimune Group by 562,400.0% in the 1st quarter. Essential Partners LLC now owns 5,625 shares of the company's stock worth $43,000 after acquiring an additional 5,624 shares during the last quarter. Finally, BNP Paribas Financial Markets grew its holdings in shares of Replimune Group by 99.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 13,762 shares of the company's stock worth $58,000 after acquiring an additional 6,873 shares during the last quarter. Institutional investors and hedge funds own 92.53% of the company's stock.

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company's proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune's lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source